Greenland Mines Ltd (NASDAQ: GRML) announced that its board of directors has adopted a limited-duration stockholder rights plan, effective July 22, 2026, to protect stockholders from coercive takeover tactics and ensure they receive full and fair value in connection with any proposal to acquire the company or obtain control. The rights plan, commonly known as a "poison pill," will remain in effect for one year unless redeemed, exchanged, or otherwise terminated earlier.
Under the plan, rights generally become exercisable if a person or group acquires beneficial ownership of 15% or more of the company's outstanding common shares, with certain existing holders grandfathered under specified conditions. Greenland Mines said the plan is intended to provide the board with time to evaluate acquisition proposals and does not prevent it from considering or accepting offers determined to be in the best interests of stockholders. The full press release is available at https://ibn.fm/VilQp.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho's KLTO-202 primary indication for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The adoption of the rights plan comes amid heightened interest in critical minerals, including rare earth elements, which are essential for various high-tech and defense applications. Greenland Mines' Skaergaard Project is one of the world's largest undeveloped palladium and platinum deposits, and the Sarfartoq project is a significant source of Nd-Pr, a key component in permanent magnets used in electric vehicles and wind turbines. The biotech division, with its focus on ALS, adds another layer of strategic value.
The rights plan is a defensive measure that signals the board's commitment to preventing any party from gaining control without paying a fair premium. It also provides the board with leverage in any potential negotiation. The one-year duration is notable, as it suggests the company may be expecting or preparing for a potential acquisition attempt. For more information on the latest news and updates relating to GRML, visit the company's newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company's SEC filings. All parties undertake no duty to update this information unless required by law.
